1. Medtech Insight
  2. >>Policy & Regulation

Congress To Focus On Cures And MACRA Oversight, MDUFA In 2017

 
• By Sue Darcey

Congressional health committees will spend time in 2017 focusing on oversight of agencies' implementation of the 21st Century Cures Act and the Medicare Authorization and CHIP Reauthorization Act, as well as five-year reauthorization of the medical device and prescription drug user fee acts.

FDA and CMS can look forward to a series of oversight hearings focusing on the Cures Act and the Medicare Authorization and CHIP Reauthorization (MACRA) from key Senate and House health committees, according to congressional staffers.

The Cures Act was signed into law Dec. 13 (Also see "Despite Cures Boost, Lingering Appropriations Means FDA Device Funding Still An Unknown For 2017" - Medtech Insight, 15...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legislation

More from Policy & Regulation

Inclusive By Design: UK Invites Sponsors To Submit Trial Diversity Plans

 
• By Vibha Sharma

The UK has issued clearer guidance to help drug and medical device sponsors demonstrate how they intend to include a diverse and relevant range of participants in their clinical trials.

Plans For Specific EU Orphan And Pediatric Device Expert Panel Need To Go Further

 
• By Amanda Maxwell

Moves are at last underway for a more specific focus on orphan and pediatric devices. They are a start; but experts are calling for more to support this sector.

First Alzheimer’s Disease Diagnostic Blood Test Cleared By FDA

 
• By Natasha Barrow

Fujirebio Diagnostics' Alzheimer's disease test, Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, has been cleared by the US FDA.